Distinct lithium-induced gene expression effects in lymphoblastoid cell lines from patients with bipolar disorder
Lithium is the most commonly prescribed medication for the treatment of bipolar disorder (BD), yet the mechanisms underlying its beneficial effects are still unclear. We aimed to compare the effects of lithium treatment in lymphoblastoid cell lines (LCLs) from BD patients and controls. LCLs were generated from sixty-two BD patients (based on DSM-IV) and seventeen healthy controls matched for age, sex, and ethnicity. Patients were recruited from outpatient clinics from February 2012 to October 2014. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 19, 2017 Category: Psychiatry & Psychology Authors: Gabriel R. Fries, Gabriela D. Colpo, Nancy Monroy-Jaramillo, Junfei Zhao, Zhongming Zhao, Jodi G. Arnold, Charles L. Bowden, Consuelo Walss-Bass Source Type: research
Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior
A high ω6/ω3 ratio [fatty acid (FA) index] in the cell membrane has been associated with inadequate brain development. It has started to be used as a biomarker of treatment efficacy in human diseases. The aim of this study was to investigate if omega-3 supplementation improves erythrocyte membrane ω6/ω 3, plasma antioxidant status (TAS) and autistic behaviors. A randomized, crossover, placebo-controlled study was designed to investigate the effect of 8 weeks of supplementation with ω3 (962mg/d and 1155mg/d for children and adolescents, respectively). (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 18, 2017 Category: Psychiatry & Psychology Authors: Mara Parellada, Cloe Llorente, Rosa Calvo, Silvia Gutierrez, Luisa L ázaro, Montserrat Graell, Maria Guisasola, Maria Luisa Dorado, Leticia Boada, Jose Romo, Elena Dulin, Inmaculada Sanz, Celso Arango, Carmen Moreno Source Type: research
Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders
This study aims to explore whether individuals with ADHD and comorbid SUD are treated with higher stimulant doses than individuals with ADHD only, and whether doses increase over time as a sign of tolerance, a core symptom of addiction. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 18, 2017 Category: Psychiatry & Psychology Authors: Charlotte Skoglund, Lena Brandt, Brian D ’Onofrio, Henrik Larsson, Johan Franck Source Type: research
Repeated cortisol administration does not reduce intrusive memories – A double blind placebo controlled experimental study
PTSD is a severe mental disorder, which may develop after exposure to traumatic events and is characterized by intrusive memories. Intrusions are sudden brief sensory memories of the traumatic event, that cause immense distress and impairment in every day functioning. Thus, the reduction of intrusive memories is one of the main aims of PTSD therapy. Recently, the glucocorticoid cortisol has been proposed as a pharmacological option to reduce intrusive memories, because cortisol is known to have memory retrieval inhibiting effects. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 18, 2017 Category: Psychiatry & Psychology Authors: Alexandra Heike Graebener, Tanja Michael, Elena Holz, Johanna Lass-Hennemann Source Type: research
Anterior cingulate cortex grey matter volume abnormalities in adolescents with PTSD after childhood sexual abuse
Adverse childhood experiences (ACE) substantially increase the risk of later psychiatric and somatic pathology. While neurobiological factors are likely to play a mediating role, specific insights are lacking. The scarce neuroimaging studies in traumatised pediatric populations have provided inconsistent results, potentially due to the inclusion of different types of trauma. To further improve our understanding of the neurobiology of pediatric psychotrauma, this study seeks to investigate abnormalities in grey matter volume (GMV) in a homogeneous group of adolescents with posttraumatic stress disorder (PTSD) due to childho...
Source: European Neuropsychopharmacology - September 6, 2017 Category: Psychiatry & Psychology Authors: Mirjam A. Rinne-Albers, J. Nienke Pannekoek, Marie-José van Hoof, Natasja D. van Lang, Francien Lamers-Winkelman, Serge A. Rombouts, Nic J. van der Wee, Robert R. Vermeiren Source Type: research
Low adherence to antidepressants is associated with increased mortality following stroke: A large nationally representative cohort study
Post stroke depression is common and pervasive. In the general population, there has been some controversy that antidepressant (AD) medication is associated with premature mortality. Data is still lacking regarding the association between adherence to antidepressants (AD) and all-cause mortality. In this retrospective analysis of a population-based cohort of patients, 32,361 post-stroke patients who purchased at least one AD were followed for all-cause mortality over 4-years. Adherence to AD was measured as a ratio between dispensed and prescribed durations and was modeled as: non-adherence (80%, n=12,978) adherence. (Sour...
Source: European Neuropsychopharmacology - September 5, 2017 Category: Psychiatry & Psychology Authors: Amir Krivoy, Brendon Stubbs, Ran D. Balicer, Shira Weizman, Becca Feldman, Moshe Hoshen, Gil Zalsman, Eldar Hochman, Gal Shoval Source Type: research
Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial
Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 4, 2017 Category: Psychiatry & Psychology Authors: Marina Garriga, Eva Sol é, Ana González-Pinto, Gabriel Selva-Vera, Belén Arranz, Benedikt L. Amann, Jerónimo Saiz-Ruiz, Josefina Pérez-Blanco, Eduard Vieta Source Type: research
Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response
Dopamine (DA) neurotransmission within the brain's reward circuit has been implicated in the pathophysiology of depression and in both, cognitive and pharmacological mechanisms of treatment response. Still, a direct relationship between measures of DA neurotransmission and reward-related deficits in patients with depression has not been demonstrated. To gain insight into the symptom-specific alterations in the DA system in patients with depression, we used positron emission tomography (PET) and the D2/3 receptor-selective radiotracer [11C]raclopride in twenty-three non-smoking un-medicated Major Depressive Disorder (MDD) p...
Source: European Neuropsychopharmacology - September 1, 2017 Category: Psychiatry & Psychology Authors: Marta Peci ña, Magdalena Sikora, Erich T. Avery, Joseph Heffernan, Susana Peciña, Brian J. Mickey, Jon-Kar Zubieta Source Type: research
Treatment with a GLP −1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP −1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar diso rder (BD) were recruited. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - September 1, 2017 Category: Psychiatry & Psychology Authors: Rodrigo B. Mansur, Andre Zugman, Juhie Ahmed, Danielle S. Cha, Mehala Subramaniapillai, Yena Lee, Julie Lovshin, Jung G. Lee, Jae-Hon Lee, Vladislav Drobinin, Jason Newport, Elisa Brietzke, Eva Z. Reininghaus, Kang Sim, Maj Vinberg, Natalie Rasgon, Tomas Source Type: research
Editorial Board
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - August 30, 2017 Category: Psychiatry & Psychology Source Type: research
ECNP Calendar of Events
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - August 30, 2017 Category: Psychiatry & Psychology Source Type: research
Contents
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - August 30, 2017 Category: Psychiatry & Psychology Source Type: research
Discrete memory impairments in largely pure chronic users of MDMA
Chronic use of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) has repeatedly been associated with deficits in working memory, declarative memory, and executive functions. However, previous findings regarding working memory and executive function are inconclusive yet, as in most studies concomitant stimulant use, which is known to affect these fu nctions, was not adequately controlled for. Therefore, we compared the cognitive performance of 26 stimulant-free and largely pure (primary) MDMA users, 25 stimulant-using polydrug MDMA users, and 56 MDMA/stimulant-naïve controls by applying a comprehensive neuropsycholog...
Source: European Neuropsychopharmacology - August 30, 2017 Category: Psychiatry & Psychology Authors: Michael D. Wunderli, Matthias Vonmoos, Marina F ürst, Katrin Schädelin, Thomas Kraemer, Markus R. Baumgartner, Erich Seifritz, Boris B. Quednow Source Type: research
Time-dependent role of prefrontal cortex and hippocampus on cognitive improvement by aripiprazole in olfactory bulbectomized mice
Dopamine (DA) modulates cognitive functions in the prefrontal cortex (PFC) and hippocampus. Olfactory bulbectomy (OBX) in mice induces cognitive dysfunctions. Recently, we reported that aripiprazole (ARI) normalizes the behavioral hyper-responsivity to DA agonists in OBX mice. However, it remains unclear whether ARI affects OBX-induced cognitive dysfunctions. To address this question we evaluated ARI-treated and untreated OBX mice in a passive avoidance test. Then, we investigated the effects of ARI on cell proliferation in the hippocampal dentate gyrus by immunohistochemistry, and on c-fos levels in the PFC and hippocampu...
Source: European Neuropsychopharmacology - August 16, 2017 Category: Psychiatry & Psychology Authors: Kohei Takahashi, Osamu Nakagawasai, Wataru Nemoto, Takayo Odaira, Yuichiro Arai, Tadashi Hisamitsu, Koichi Tan-No Source Type: research
A positron emission tomography study of the serotonergic system in relation to anxiety in depression
Symptoms of anxiety are highly comorbid with major depressive disorder (MDD) and are known to alter the course of the disease. To help elucidate the biological underpinnings of these prevalent disorders, we previously examined the relationship between components of anxiety (somatic, psychic and motoric) and serotonin 1A receptor (5-HT1A) binding in MDD and found that higher psychic and lower somatic anxiety was associated with greater 5-HT1A binding. In this work, we sought to examine the correlation between these anxiety symptom dimensions and 5-HTT binding. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - August 12, 2017 Category: Psychiatry & Psychology Authors: Zafer Iscan, Gopalkumar Rakesh, Samantha Rossano, Jie Yang, Mengru Zhang, Jeffrey Miller, Gregory M. Sullivan, Priya Sharma, Matthew McClure, Maria A. Oquendo, J. John Mann, Ramin V. Parsey, Christine DeLorenzo Source Type: research
